Enveric Biosciences ENVB
NASDAQ ENVB
$1.48 +0.02 (+1.37%)
At close: Oct 2, 2026 · 4:00 PM EDT

Enveric Biosciences (ENVB) Gains from Sales and Divestitures (2020 - 2023)

Updated

Enveric Biosciences (ENVB) posted Gains from Sales and Divestitures of -$13.00 for Q4 2023.

Analysis

Enveric Biosciences (ENVB) Gains from Sales and Divestitures (2020 - 2023) Analysis & Trends

For FY2023, Enveric Biosciences' Gains from Sales and Divestitures came in at $4,206.

  • Annual Gains from Sales and Divestitures shows a five-year compound annual growth rate of 14.5% (FY2018 to FY2023).
  • In prior years, Enveric Biosciences' Gains from Sales and Divestitures was $11,386 in FY2019 (+432.3%).
  • The Q4 2023 figure stands as the lowest quarterly Gains from Sales and Divestitures since Q2 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Enveric Biosciences 5.83 Mn -15.82 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -13.00
Sep 30, 2023 7.00
Jun 30, 2020 -21,611.00
API Access

Enveric Biosciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ENVB&period=max&api_key=YOUR_API_KEY